Edaravone Ameliorates Oxidative Damage Associated with Aβ25-35 Treatment in PC12 Cells

Oxidative damage is an important mediator of Alzheimer’s disease (AD); hence, antioxidant therapy is a potential treatment for AD. Edaravone, a free radical scavenger, has been shown to have neuroprotective properties. The study aimed to examine the effects of edaravone on indicators of Aβ25-35-induced oxidative damage in PC12 cells. PC12 cells were treated with 20, 40, or 80 μM edaravone before treatment with 30 μM Aβ25-35. After treatment, the...